CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2024—BD announced it has received FDA 510(k) clearances for its BD MiniDraw, a novel blood collection device that obtains blood samples from a fingerstick. The clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit testing.
The regulatory clearances pave the way for Babson Diagnostics to bring its BetterWay blood testing service, which includes the BD MiniDraw, to market this year. BD and Babson announced in May 2022 an expansion of their strategic partnership agreement to advance the development of the BetterWay testing service.
Babson Diagnostics, 512-562-2473
BD, 201-847-6800